230 related articles for article (PubMed ID: 29136723)
1. [The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)].
; ;
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):866-870. PubMed ID: 29136723
[TBL] [Abstract][Full Text] [Related]
2. [The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)].
; ;
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):341-346. PubMed ID: 32370461
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults.
Guerard EJ; Tuchman SA
Clin Geriatr Med; 2016 Feb; 32(1):191-205. PubMed ID: 26614868
[TBL] [Abstract][Full Text] [Related]
6. Clinical practice. Monoclonal gammopathy of undetermined significance.
Bladé J
N Engl J Med; 2006 Dec; 355(26):2765-70. PubMed ID: 17192542
[No Abstract] [Full Text] [Related]
7. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
Deighan WI; O'Kane MJ; McNicholl FP; Keren DF
Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Gammopathy of Renal Significance-A Rare Renal Presentation: A Review of Cases Reported.
Kichloo A; Nawaz N; Singh J; Aljadah M; Albosta MS; Bhanot R
J Investig Med High Impact Case Rep; 2020; 8():2324709620940500. PubMed ID: 32643956
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
11. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.
Samaras P; Bargetzi M; Betticher DC; Duchosal MA; Heim D; Hess U; Ketterer N; Lerch E; Matthes T; Mey U; Pabst T; Taverna C; Zander T; Renner C
Swiss Med Wkly; 2015; 145():w14100. PubMed ID: 25999239
[TBL] [Abstract][Full Text] [Related]
12. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
[No Abstract] [Full Text] [Related]
13. [The CBO professional guideline 'monoclonal gammopathy' (paraproteinemia) (revision)].
Buiting AM; Wijermans PW
Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1406-11. PubMed ID: 12174434
[TBL] [Abstract][Full Text] [Related]
14. [The pathology and genetic background of myeloma].
Timár B
Magy Onkol; 2016 Jun; 60(2):145-53. PubMed ID: 27275641
[TBL] [Abstract][Full Text] [Related]
15. Advances in the diagnosis and management of myeloma.
Greipp PR
Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
[No Abstract] [Full Text] [Related]
16. [Smoldering multiple myeloma].
Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
[TBL] [Abstract][Full Text] [Related]
17. A case study progression to multiple myeloma.
Yancey MA; Waxman AJ; Landgren O
Clin J Oncol Nurs; 2010 Aug; 14(4):419-22. PubMed ID: 20682498
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma: clinical features and indications for therapy.
Dispenzieri A; Kyle RA
Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
[TBL] [Abstract][Full Text] [Related]
19. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS; Tombler ER; Stadtmauer E; Jagannath S; Anderson KC;
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):356-69. PubMed ID: 25066040
[TBL] [Abstract][Full Text] [Related]
20. [Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
;
Zhonghua Nei Ke Za Zhi; 2022 May; 61(5):480-487. PubMed ID: 35488597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
